« Return to News | Awards & Advancement

Averion Names Executive Vice President of Global Biz Dev

Wednesday, August 20, 2008 09:00 AM

Averion International, an international contract research organization (CRO) specializing in oncology and cardiovascular diseases, appointed Peter Gonze executive vice president of global business development, a role that will focus on increasing Averion’s business efforts in international markets.

“We will continue to pursue new business opportunities in North America and Europe, and plan to expand our geographic and therapeutic capabilities in emerging regions of the world,” chief executive officer Markus H. Weissbach, M.D., said in a company release.

Gonze brings more than 35 years of pharma-related experience to Averion. He’s held senior-level positions at GlaxoSmithKline, RhonePoulenc Rorer (now SanofiAventis), Johnson & Johnson, Abbott Diagnostics-Medisense and AltaRed, and, most recently, he was chief operating officer of Unither Pharmaceuticals, a company focused on immunotherapeutic vaccines for oncology.

Averion isn’t the only company in the clinical trials industry creating positions to advance their global aspirations. Earlier this month, SpineMark Corporation, the parent company of SpineMark CRO, named Dr. Rudolf Bertagnoli chairman of its International Medical Advisory Board in an effort to strengthen its international presence.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.